Abstract
In Germany, over six million people suffer from osteoporosis. Nearly half of the women
over 70 years and nearly 20 % of men at the same age are affected. The clinical and
socioeconomical relevance of the disease lies in osteoporotic fractures leading to
extensive bone-associated morbidity, increased mortality and health care costs. Fracture
risk algorithms and guidelines for the diagnosis and treatment of osteoporosis help
to assess the individual fracture risk. By calculating the individual fracture risk,
the indication for specific osteoporosis treatment can objectively be determined.
A consequent specific osteoporosis therapy is required for patients with a high fracture
risk and is essential to prevent osteoporotic fractures and their consequences. As
first-line therapy a drug with a proven fracture-reducing effect should be taken.
However, for successful osteoporosis therapy, many individual factors have to be considered.
A personalized treatment approach should be established according to the severity
of the disease, the patient’s sex and comorbidities as well as the possible additive
and side effects of the drug.
Rund 6 Millionen Menschen sind in Deutschland an Osteoporose erkrankt, überwiegend
Frauen nach den Wechseljahren. Aber auch andere Patientengruppen sind betroffen, z. B.
bei Langzeit-Einnahme von Glukokortikoiden. Es gibt klare Empfehlungen zur Behandlung
der Osteoporose. Der Praktiker sollte diese kennen und darüber hinaus wissen, welche
individuellen Faktoren (v. a. Komorbiditäten) neben der Ursache zu berücksichtigen
sind.
Schlüsselwörter
Osteoporose - personalisierte Therapie - Bisphosphonate - Denosumab - Teriparatid
Key words
osteoporosis - personalized therapy - bisphosphonates - denosumab - teriparatide
